Reaction
Mastitis reporting signals
As of the last recalculation, Mastitis appears in 1,861 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is PERTUZUMAB (PRR 22.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pertuzumab | 52 | 22.0 | 22.0 |
| Anastrozole Tablets | 26 | 13.7 | 13.7 |
| Trastuzumab | 72 | 12.2 | 12.2 |
| Anastrozole | 34 | 10.5 | 10.5 |
| Clindamycin | 25 | 10.0 | 10.0 |
| Ribociclib | 27 | 9.7 | 9.7 |
| Ado-Trastuzumab Emtansine | 7 | 9.3 | 9.3 |
| Risperidone | 100 | 8.8 | 8.8 |
| Abemaciclib | 15 | 8.5 | 8.5 |
| Infliximab-Dyyb | 21 | 8.1 | 8.1 |
| Letrozole | 43 | 8.0 | 8.0 |
| Tranexamic Acid | 6 | 7.6 | 7.6 |
| Letrozole Tablets | 31 | 7.3 | 7.3 |
| Docetaxel Anhydrous | 38 | 6.4 | 6.4 |
| Docetaxel | 38 | 6.4 | 6.4 |
| Ocrelizumab | 30 | 5.5 | 5.5 |
| Ustekinumab | 49 | 5.5 | 5.5 |
| Palbociclib | 44 | 5.3 | 5.3 |
| Canakinumab | 5 | 5.2 | 5.2 |
| Certolizumab Pegol | 51 | 5.0 | 5.0 |
| Paclitaxel | 39 | 4.5 | 4.5 |
| Asenapine Maleate | 3 | 3.9 | 3.9 |
| Medroxyprogesterone Acetate | 17 | 3.8 | 3.8 |
| Temozolomide | 7 | 3.7 | 3.7 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 3.0 | 3.0 |
| Sarilumab | 6 | 2.5 | 2.5 |
| Pegfilgrastim | 22 | 2.5 | 2.5 |
| Levonorgestrel | 30 | 1.7 | 1.7 |